Futura Medical raises $2.2M and puts itself up for sale
What's the deal? UK consumer healthcare group Futura MedicalDealroom has a profile for this one. Try Dealroom → has conditionally raised roughly £1.6 million ($2.2 million) in a post-IPO equity round and simultaneously launched a formal sale process, opening the door to a potential takeover.
The details: The AIM-listed company (AIM: FUM) placed 801,000,000 new ordinary shares at 0.2 pence each through a placing and subscription. It also plans a retail offer to raise up to a further £150,000.
Why now? Futura, the group behind erectile dysfunction gel Eroxonon, said its market valuation does not reflect the strategic potential of its portfolio. The new funds extend its cash runway into February 2027, buying time to explore its options.
What's the endgame? The company pointed to WSD4000, a product it estimates could reach peak annual consumer sales above $400 million. The M&A and formal sale process could see the whole company or individual assets sold to unlock that value.
What could go wrong? The sale process carries no guarantees. As Futura noted under UK takeover rules, there "can be no certainty that an offer will be made" nor on what terms.
The signal: Raising just enough to keep the lights on while inviting bidders is a familiar move for small-cap firms whose share price has drifted below what management sees as fair. For Futura, the quick top-up is less about growth capital than about staying solvent long enough to find a buyer.
Read more: investegate.co.uk
Image credit: umseas
